Inhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations.

[1]  E. Dennis,et al.  Inhibition of group IVA cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo. , 2004, Journal of medicinal chemistry.

[2]  M. Moskowitz,et al.  Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2 , 1997, Nature.

[3]  M. Gelb,et al.  Biochemistry and physiology of mammalian secreted phospholipases A2. , 2008, Annual review of biochemistry.

[4]  Zhenming Liu,et al.  Multiple-Docking and Affinity Fingerprint Methods for Protein Classification and Inhibitors Selection , 2009, J. Chem. Inf. Model..

[5]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[6]  E. Mombelli,et al.  3D QSAR Study of Human PLA2 Inhibitors. A Modeling Approach to Select New and Specific Anti-Inflammatory Drugs , 2006 .

[7]  E. Dennis,et al.  Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2. , 2007, Journal of medicinal chemistry.

[8]  E. Dennis,et al.  Differential inhibition of group IVA and group VIA phospholipases A2 by 2-oxoamides. , 2006, Journal of medicinal chemistry.

[9]  M. J. D. Powell,et al.  Restart procedures for the conjugate gradient method , 1977, Math. Program..

[10]  E. Dennis,et al.  Synthesis and activity of 2‐oxoamides containing long chain β‐amino acids , 2005 .

[11]  R. Rosenson.  Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease , 2009, Cardiovascular Drugs and Therapy.

[12]  Patrick W Serruys,et al.  Phospholipase A2 inhibitors , 2009, Current opinion in lipidology.

[13]  P. Sigler,et al.  Structure and catalytic mechanism of secretory phospholipases A2. , 1994, Advances in protein chemistry.

[14]  D. Clawson,et al.  Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2 Å resolution , 1991, Nature.

[15]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[16]  R. Kramer,et al.  Structure and properties of a human non-pancreatic phospholipase A2. , 1989, The Journal of biological chemistry.

[17]  James G. Bollinger,et al.  Inhibition of the complete set of mammalian secreted phospholipases A(2) by indole analogues: a structure-guided study. , 2004, Bioorganic & medicinal chemistry.

[18]  Richard D. Taylor,et al.  Modeling water molecules in protein-ligand docking using GOLD. , 2005, Journal of medicinal chemistry.

[19]  R. Reid,et al.  Inhibitors of secretory phospholipase A2 group IIA. , 2005, Current medicinal chemistry.

[20]  Virgil L. Woods,et al.  Location of inhibitors bound to group IVA phospholipase A2 determined by molecular dynamics and deuterium exchange mass spectrometry. , 2009, Journal of the American Chemical Society.

[21]  Jeremy R. Greenwood,et al.  Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..

[22]  E. Dennis,et al.  Phospholipase A2 Biochemistry , 2009, Cardiovascular Drugs and Therapy.

[23]  V. Magrioti,et al.  Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases , 2010, Expert opinion on therapeutic patents.

[24]  Thomas M. Mavromoustakos,et al.  Molecular Docking and 3D-QSAR CoMFA Studies on Indole Inhibitors of GIIA Secreted Phospholipase A2 , 2010, J. Chem. Inf. Model..

[25]  Luhua Lai,et al.  Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.

[26]  Jennifer L. Martin,et al.  D‐Tyrosine as a Chiral Precusor to Potent Inhibitors of Human Nonpancreatic Secretory Phospholipase A2 (IIa) with Antiinflammatory Activity , 2003, Chembiochem : a European journal of chemical biology.

[27]  S S Abdel-Meguid,et al.  High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX). , 1996, Journal of medicinal chemistry.

[28]  Jonathan W. Essex,et al.  A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..

[29]  Ruth Nussinov,et al.  Principles of docking: An overview of search algorithms and a guide to scoring functions , 2002, Proteins.

[30]  Thomas M. Mavromoustakos,et al.  Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor , 2010, J. Comput. Aided Mol. Des..

[31]  E. Dennis,et al.  Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. , 2008, Bioorganic & medicinal chemistry.

[32]  J.-P. Wery,et al.  Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2 , 1995, Nature Structural Biology.

[33]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[34]  J. J. Rosa,et al.  Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. , 1993, Science.

[35]  C. Leslie,et al.  Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2. , 2004, Prostaglandins, leukotrienes, and essential fatty acids.

[36]  D. Dess,et al.  A useful 12-I-5 triacetoxyperiodinane (the Dess-Martin periodinane) for the selective oxidation of primary or secondary alcohols and a variety of related 12-I-5 species , 1991 .

[37]  E. Dennis,et al.  Novel 2-oxoamide inhibitors of human group IVA phospholipase A(2). , 2002, Journal of medicinal chemistry.

[38]  C. D. Gelatt,et al.  Optimization by Simulated Annealing , 1983, Science.

[39]  M. Gelb,et al.  Interfacial Kinetic and Binding Properties of the Complete Set of Human and Mouse Groups I, II, V, X, and XII Secreted Phospholipases A2 * , 2002, The Journal of Biological Chemistry.

[40]  K. Tomoo,et al.  X-ray crystal structure determination and molecular dynamics simulation of prophospholipase A2 inhibited by amide-type substrate analogues. , 1997, Biochimica et biophysica acta.

[41]  M. Gelb,et al.  Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. , 2008, Journal of medicinal chemistry.

[42]  J. Miyazaki,et al.  Role of cytosolic phospholipase A2 in allergic response and parturition , 1997, Nature.